Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Active psoriatic arthritis (PsA) as per the Classification criteria for Psoriatic Arthritis (CASPAR) criteria, based on the investigator's clinical judgement.~* Adult patients (≥18 years of age) with PsA~* Prescribing physician has decided to initiate treatment with Otezla®, and this decision was prior to and independent of patient enrollment in the study.~* Access to commercially available Otezla®~Exclusion Criteria:~* Patients who are pregnant, breastfeeding, or who are planning on becoming pregnant during the course of the study~* Participation in Investigational Clinical Trial within the last 60 days.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Psoriatic Arthritis patients treated with Apremilast (Type: None): Active PsA as per the CASPAR criteria, based on the investigator's clinical judgement with access to commercially available Otezla

Based on this trial design, predict the completion outcome and termination type (if applicable).